GC Green Cross and Korea Vaccine Sign MOU for Vaccine PFS CMO Cooperation

GC Green Cross and Korea Vaccine announced on July 10 that they had signed a memorandum of understanding (MOU) on July 9 at the headquarters of Korea Vaccine in Ansan, Gyeonggi Province, to cooperate in the vaccine contract manufacturing organization (CMO) business. Through this agreement, the two companies plan to establish a comprehensive partnership across the entire vaccine pre-filled syringe (PFS) CMO business.

Shin Woong, Head of Operations at GC Green Cross (left), and Honggyo Park, Factory Manager of Korea Vaccine Bioplant, taking a commemorative photo. GC Green Cross

Under this agreement, GC Green Cross will diversify the finished product manufacturing infrastructure for its flagship flu vaccine, "GCFLU." The company explained that the aim is to mitigate domestic and international supply chain risks and respond to market volatility. The agreement is also significant in that it enables GC Green Cross to preemptively establish a stable manufacturing and supply network for the high-immunogenicity (high-antigen content) influenza vaccine for seniors, which the company is developing with the goal of obtaining product approval within the next three years.

The company added that this initiative is intended to secure, in advance, finished vaccine production capacity that can be immediately activated in the event of a global public health crisis or pandemic.

Korea Vaccine possesses top-tier GMP-certified production facilities that meet the standards of the World Health Organization (WHO) Pre-Qualification (PQ) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Based on this, the company provides stable contract manufacturing services for a variety of biopharmaceuticals, including seasonal influenza vaccines and intradermal BCG vaccines, and has been recognized for its process competitiveness.

Shin Woong, Head of Operations at GC Green Cross, stated, "By combining the core competencies of both companies through this agreement, we will enhance supply chain stability and contribute to supplying high-quality vaccines in a timely manner."

Honggyo Park, Plant Manager of Bioplant at Korea Vaccine, said, "Through this agreement with GC Green Cross, Korea's leading vaccine company, we have been able to establish an even faster and more stable vaccine supply system," adding, "I am very pleased and honored that this will allow us to play a greater role in promoting public health in Korea."

This content was produced with the assistance of AI translation services.